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Introduction: The PARAMOUNT Phase III trial showed that main-
tenance pemetrexed after pemetrexed plus cisplatin induction was 
well tolerated and effective for patients with advanced nonsquamous 
non–small-cell lung cancer. Approximately 17% of patients receiv-
ing maintenance therapy in this study were 70 years of age or older. 
Here we report efficacy and safety results from the PARAMOUNT 
study for elderly (≥70 years) and non-elderly (<70 years) patients.
Methods: Final efficacy and safety data from the PARAMOUNT 
study were analyzed post hoc using subgroup analyses for elderly 
and non-elderly patients.
Results: The median age was 73 years in the elderly subgroup (n = 92) 
and 60 years in the non-elderly subgroup (n = 447). Subgroups had 
similar baseline characteristics, except for a higher percentage of 
males and patients with a performance status of one in the elderly 
subgroup. For elderly patients, the median PFS was 6.4 months for 
pemetrexed and 3.0 months for placebo; the median OS was 13.7 
months for pemetrexed and 12.1 months for placebo. For non-elderly 
patients, the median PFS was 4.0 months for pemetrexed and 2.8 
months for placebo; the median OS was 13.9 months for pemetrexed 
and 10.8 months for placebo. Elderly patients experienced similar 
levels of low-grade toxicities, but had a higher percentage of grade 
3/4 anemia and neutropenia than non-elderly patients, although 
importantly, this did not translate into increased febrile neutropenia.
Conclusions: Continuation maintenance pemetrexed had compa-
rable survival and toxicity profiles in the elderly and non-elderly 
subgroups. However, grade 3/4 anemia and neutropenia were numer-
ically higher for elderly patients.
Key Words: Non–small-cell lung cancer, Pemetrexed, Elderly, 
Maintenance therapy
(J Thorac Oncol. 2014;9: 991–997)
A patient’s age is a critical factor in the treatment of can-cers.1,2 Older patients are often underrepresented in 
clinical trials and undertreated in the clinic, because of con-
cerns that they may be unable to tolerate certain therapies.1,2 
However, the incidence of lung cancer increases with age, and 
approximately half of patients with non–small-cell lung can-
cer (NSCLC) are older than 65 years, and 30–40% are older 
than 70 years.1,3 Thus, many patients with advanced NSCLC 
may not receive the treatments and benefits available for 
NSCLC, solely because of their age. Indeed, despite the high 
percentage of older patients who are diagnosed with cancer, 
few clinical trials in advanced cancers have been conducted to 
directly address the efficacy and safety of therapies for elderly 
patients. In addition, the age at which a person is considered 
elderly varies across the world and among agencies. The 
United States Food and Drug Administration and the European 
Union Committee for Medicinal Products for Human Use 
consider individuals 65 years and older as elderly; however, 
the International Society of Geriatric Oncology, the American 
Society of Clinical Oncology, and clinical trial registries often 
consider individuals 70 years and older as elderly.4–7
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Although in general, elderly patients have more comor-
bidities and greater concomitant medication use than non-
elderly patients, overall patient health varies considerably and 
is not entirely dependent on age. According to international 
guidelines, there is no evidence for the selection of specific 
first-line chemotherapy drugs or drug combinations based on 
age alone.6,8 Early concerns existed that platinum-based thera-
pies may be too toxic for elderly patients; thus, the standard 
and recommended approach in unselected elderly patients was 
single agent chemotherapy with a third-generation agent (e.g., 
vinorelbine, gemcitabine, or taxanes).5,6,8 However, several 
recent studies and updated international treatment guidelines 
suggest that elderly patients without major comorbidities and 
with a good performance status (PS; defined as 0 or 1) may 
benefit from platinum-based therapies and could be treated 
like non-elderly patients.5,6,8–13
For patients with nonsquamous NSCLC and a good 
PS, the European Society for Medical Oncology guidelines 
recommend pemetrexed and cisplatin for first-line NSCLC 
treatment.8 A retrospective analysis of Scagliotti et al.14 and 
Ciuleanu et al.15 also suggested that pemetrexed therapy may 
be a viable option for elderly patients with nonsquamous 
NSCLC, either in combination with cisplatin in the first-line 
setting or as maintenance therapy after initial platinum-based, 
non-pemetrexed containing chemotherapy.10 Recently, results 
from the PARAMOUNT trial showed that patients with non-
squamous NSCLC who had a good PS and had not progressed 
after completing four cycles of pemetrexed-cisplatin induction 
therapy benefitted from pemetrexed continuation maintenance 
therapy.16,17 Patients who received pemetrexed continuation 
maintenance therapy had significantly longer median progres-
sion-free survival (PFS) and overall survival (OS) compared 
with patients receiving placebo (median PFS: 4.1 versus 2.8 
months, respectively, hazard ratio (HR) = 0.62, p < 0.0001; 
median OS: 13.9 versus 11.0 months, respectively, HR = 0.78, 
p = 0.0195).16,17 Pemetrexed continuation maintenance therapy 
was well tolerated, and patients were able to maintain their 
quality of life.16,17 The OS and PFS benefits from pemetrexed 
were also observed across all subgroups analyzed, including 
age, disease stage, and induction response.16,17
To obtain additional critical information regarding the 
elderly subpopulation during maintenance therapy with peme-
trexed, we analyzed data from the PARAMOUNT Phase III 
trial. Here, we provide a descriptive post hoc subgroup anal-
ysis of the elderly (≥70 years) and non-elderly (<70 years) 
patients in the PARAMOUNT study during the maintenance 
phase and provide PFS, OS, toxicity, and resource utilization 
data for these age-based subgroups.
METHODS
Study Design and Patients
PARAMOUNT was a Phase III, multicenter, random-
ized double-blind study of patients with advanced or meta-
static NSCLC. Consenting adult patients with stage IIIB or 
IV nonsquamous NSCLC without prior systemic chemother-
apy for lung cancer and an Eastern Cooperative Oncology 
Group PS of 0 or 1 were eligible for the study. For additional 
details on enrollment, patient disposition and trial design, 
see Paz-Ares et al.16,17 The study consisted of an induction 
phase in which 939 patients received pemetrexed (500 mg/
m2 intravenously [IV]) and cisplatin (75 mg/m2 IV) on day 
1 of a 21 day cycle, for four cycles. All patients received 
vitamin B12, folic acid supplementation, and prophylactic 
dexamethasone according to the pemetrexed label.18 For the 
maintenance phase, patients who had not progressed and had 
a PS of 0 or 1 after completing four cycles of pemetrexed 
plus cisplatin induction therapy were randomized 2:1 (strati-
fied for stage, PS, and induction response) to receive either 
maintenance pemetrexed (500 mg/m2 IV) plus best support-
ive care (n = 359) on day 1 of 21 day cycles or placebo plus 
best supportive care (n = 180). Discontinuation of mainte-
nance therapy occurred on disease progression, unacceptable 
toxicity, or because of patient or physician request. Patients 
were followed until the end of the study or death.
Before the initiation of the trial, site-specific ethics 
review boards approved the trial. Before treatment initiation, 
patients provided written informed consent. The study was 
conducted according to the principles of good clinical practice 
and the Declaration of Helsinki.
Subgroup Analyses
The PARAMOUNT study was powered for both the 
primary objective of PFS and for a key secondary objective 
of OS. Some subgroup analyses were prespecified in the sta-
tistical analysis plan for the PARAMOUNT trial. Subgroups 
based on age were defined post hoc based on the patients’ ages 
at the time of randomization. Patients greater than 70 years 
were assigned to the elderly subgroup, and patients less than 
70 years were assigned to the non-elderly subgroup for analy-
ses. For each age group, the Kaplan-Meier method was used 
to estimate the OS and PFS for each treatment group. Data 
regarding toxicity and resource use were summarized for each 
age group.
RESULTS
During the induction phase of the PARAMOUNT trial, 
171 (18%) of patients were 70 years of age or older, whereas 
during the maintenance phase, elderly patients comprised 
17% of patients. Table 1 shows the patient and disease char-
acteristics by age subgroup and treatment arm at baseline, for 
patients who entered the maintenance phase of the trial. Age 
was not included as a stratification factor during randomiza-
tion. Thus, despite the 2:1 (pemetrexed:placebo) randomiza-
tion in the overall study population, retrospective subgroup 
analyses revealed that 52 (14%) patients who received peme-
trexed and 40 (22%) patients who received placebo were 
elderly. Patient characteristics besides age were well balanced 
among subgroups, except that a greater percentage of elderly 
patients (77%) had a PS of one compared with non-elderly 
patients (65%) and 78% of the elderly patients who received 
placebo were male compared with only 58% of non-elderly 
patients (Table 1).
Of the elderly patients in the maintenance phase, 17 
(18.5%) were at least 75 years of age. Of these 17 patients, 
13 were male, 13 had a PS of one, 15 had stage IV disease 
and nine were assigned to pemetrexed maintenance. Two male 
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patients were older than 80 years of age; both had a PS of one 
and were assigned to the placebo arm.
During the induction phase of the PARAMOUNT trial, 
the mean dose intensity received of pemetrexed was 95% 
for both the elderly (n = 171) and the non-elderly (n = 768), 
whereas the mean dose intensity of cisplatin was 94% for the 
elderly and 95% for the non-elderly. More than half (60%) of 
the elderly patients and 71% of the non-elderly patients com-
pleted 4.0 cycles of induction therapy. Table 2 shows the num-
ber of maintenance cycles administered for patients in each age 
subgroup and by treatment arm. The median and mean number 
of pemetrexed cycles was slightly higher for the non-elderly 
(median = 4.5 cycles, range 1–44 cycles; mean = 8.0 cycles, 
standard deviation [SD] = 8.4 cycles) compared with the 
elderly (median = 4.0 cycles, range 1–36 cycles; mean = 7.4 
cycles, SD = 7.3 cycles). Dose intensity was 94% and 91%, 
for non-elderly and elderly patients, respectively. The median 
number of placebo cycles completed (4.0) was the same for 
both age subgroups; the mean was slightly higher for the 
non-elderly (mean = 5.1 cycles, SD = 5.7) compared with the 
elderly (mean = 4.5 cycles, SD = 2.8); 46% of elderly patients 
who received pemetrexed completed at least six cycles and 
31% completed at least 10 cycles. This was similar to the non-
elderly subgroup in which 47% completed at least six cycles 
and 27% completed 10 or more cycles of pemetrexed (Table 2).
Sixteen of the 18 elderly patients who received greater 
than or equal to 10 cycles of maintenance treatment were in 
the pemetrexed arm. Baseline characteristics of the 16 elderly 
patients in the pemetrexed arm who received greater than or 
equal to 10 cycles were as follows: 15 had stage IV disease, 
eight had a PS of one, 10 were male and seven had a complete 
or partial response during the induction phase. The percentage 
of elderly patients with a PS of 0 in the pemetrexed arm was 
enriched at greater than or equal to 10 cycles compared with 
baseline (50% versus 23%, respectively). This trend was also 
observed in the non-elderly subgroup for patients with a PS of 
0, although the degree of enrichment there was smaller (41% 
at ≥10 cycles versus 34% at baseline). Patients in both age 
subgroups and treatment arms discontinued treatment most 
often because of progressive disease (PD). Fewer patients in 
the pemetrexed maintenance arm (50% of elderly versus 73% 
of non-elderly patients) discontinued treatment because of PD 
compared with patients in the placebo arm (90% of elderly 
patients versus 83% of non-elderly patients). The difference 
between treatment arms was higher among elderly patients.
In the pemetrexed arm, treatment discontinuations 
because of adverse events (AEs) that were possibly related 
to study drug occurred in 23% of elderly and 10% of non-
elderly patients; in 8% and 3% of patients, respectively, the 
AE causing discontinuation was serious. One-fourth of these 
discontinuations in the elderly and more than one-third in the 
non-elderly patients were because of renal events, of which 
only one occurrence in the non-elderly subgroup was serious 
TABLE 1.   Patient and Disease Characteristics for Elderly and 
Non-Elderly Subgroups
Elderly (≥70 Yrs)  
Subgroup
Non-Elderly  
(<70 Yrs) Subgroup
Pem  
(N = 52)
Plc  
(N = 40)
Pem  
(N = 307)
Plc  
(N = 140)
Median age (yrs) 72 73 60 60
Sex, n (%)
  Female 22 (42) 9 (23) 136 (44) 59 (42)
  Male 30 (58) 31 (78) 171 (56) 81 (58)
Origin, n (%)
  Caucasian 50 (96) 40 (100) 289 (94) 131 (94)
  Asian 2 (4) 0 14 (5) 8 (6)
  Black/African 
American
0 0 4 (1) 1 (0.7)
Smoking statusa, n (%)
  Ever smoker 40 (77) 31 (78) 234 (76) 113 (81)
  Never smoker 11 (21) 8 (20) 72 (24) 26 (19)
ECOG PS, n (%)
  0 12 (23) 8 (20) 101 (33) 52 (37)
  1 39 (75) 32 (80) 206 (67) 86 (61)
  2/3b 1 (2) 0 0 2 (1)
Stagec, n (%)
  IIIB 6 (12) 3 (8) 25 (8) 15 (11)
  IV 46 (89) 37 (93) 282 (92) 125 (89)
Histology, n (%)
  Adenocarcinoma 46 (89) 34 (85) 264 (86) 127 (91)
  Large cell 3 (6) 3 (8) 21 (7) 9 (6)
  Other nonsquamous 3 (6) 3 (8) 22 (7) 4 (3)
Tumor response to induction, n (%)
  Complete/partial  
response
22 (42) 17 (43) 137 (45) 58 (41)
  Stable disease 28 (54) 20 (50) 162 (53) 75 (54)
  Progressive  
disease/unknownb
2 (4) 3 (8) 8 (3) 7 (5)
aUnknown: n = 1 (pem, ≥70 yrs); n = 1 (plc, ≥70 yrs); n = 1 (pem, <70 yrs); n = 1 
(plc, <70 yrs).
bProtocol violations.
cAmerican Joint Committee on Cancer Staging Criteria for Lung Cancer.
ECOG, Eastern Cooperative Oncology Group; Pem, pemetrexed; Plc, placebo; PS, 
performance status; Yrs, years.
TABLE 2.  Cycles of Maintenance Therapy Administered and 
Dose Intensity
Elderly (≥70 Yrs)  
Subgroup
Non-Elderly  
(<70 Yrs) Subgroup
Pem  
(N = 52)
Plc  
(N = 40)
Pem  
(N = 307)
Plc  
(N = 140)
Patients treated, n 51 40 306 138
Number of cycles/patient,  
median (range)
4.0 (1–36) 4.0 (1–15) 4.5 (1–44) 4.0 (1–38)
Number of cycles,  
mean (SD)
7.4 (7.3) 4.5 (2.8) 8.0 (8.4) 5.1 (5.7)
Patients completing  
≥6 cycles (%)
46 35 47 29
Patients completing  
≥10 cycles (%)
31 5 27 14
Dose intensitya (%) 91 NA 94 NA
a(Actual mean weekly dose/planned mean weekly dose) × 100.
NA, not applicable; Pem, pemetrexed; Plc, placebo; SD, standard deviation; 
Yrs, years.
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(0.3%). Hematologic toxicities (anemia, neutropenia, and 
thrombocytopenia) caused one-third of discontinuations in 
the elderly (half of them were serious adverse events [SAEs]) 
and 10% in the non-elderly (all SAEs). Fatigue caused 8% of 
discontinuations in the elderly subgroup compared with 23% 
in the non-elderly, none of these were serious.
For patients in the placebo arm, 10% of elderly and 3% 
of non-elderly patients discontinued because of an AE that was 
possibly related to the study drug. Discontinuations because of 
SAEs occurred in 3% of elderly and 1% of non-elderly patients 
in the placebo arm. Similar to discontinuations because of PD, 
the differences between treatment arms for discontinuations 
because of AEs and SAEs were higher for the elderly subgroup.
Kaplan-Meier curves showing PFS for both the elderly 
and non-elderly subgroups are shown in Fig. 1A, B. The post 
hoc subgroup analyses by age, showed that elderly and non-
elderly patients who received pemetrexed had numerically 
longer PFS than those patients in their age group who received 
placebo (Fig. 1A, B). Unadjusted HRs were reported as part of 
the primary and secondary analyses.16,17 For the elderly sub-
group, median PFS (95% confidence interval [CI]) was 6.4 
months (3.3-not evaluable) in the pemetrexed arm and 3.0 
months (1.5–4.1) in the placebo arm; unadjusted HR = 0.35 
(95% CI: 0.20–0.63),16 log-rank p = 0.0002. Median PFS 
(95% CI) for the non-elderly was 4.0 months (2.9–4.2) in 
the pemetrexed arm and 2.8 months (2.6–3.5) in the placebo 
arm; unadjusted HR = 0.69 (95% CI: 0.54–0.90),16 log-rank 
p = 0.005. Kaplan-Meier curves of OS for the elderly and non-
elderly subgroups are shown in Fig. 1C,D. Median OS times 
were comparable for the elderly and non-elderly subgroups. 
The median OS (95% CI) in the elderly subgroup was 13.7 
months (10.4–19.4) for patients who received pemetrexed and 
12.1 months (8.4–16.9) for patients who received placebo; 
unadjusted HR = 0.8917 (95% CI: 0.55–1.44), log-rank 
p = 0.628 (Fig. 1C,D). In the non-elderly subgroup, median 
OS (95% CI) was 13.9 months (12.5–16.1) for patients who 
received pemetrexed and 10.8 months (9.5–12.9) for patients 
who received placebo; unadjusted HR = 0.7517 (95% CI: 
0.60–0.95), log-rank p = 0.147 (Fig. 1C, D).
The 1- and 2-year OS rates (95% CI) for patients who 
received pemetrexed, were 60% (45–71%) and 34% (21–47%) 
for the elderly and 58% (52–63%) and 31% (26–37%) for 
the non-elderly, respectively. For patients who received pla-
cebo, the 1- and 2-year OS rates were 52% (36–66%) and 
28% (15–43%) for the elderly and 43% (35–52%) and 19% 
(13–27%) for the non-elderly subgroup, respectively.
Many elderly patients (60% in the pemetrexed arm and 
83% in the placebo arm) and non-elderly patients (65% ver-
sus 69%, respectively) received post-discontinuation systemic 
therapy (PDT). The most common PDTs were erlotinib and 
docetaxel, both of which are regulatory-approved, second-line 
treatments. PDT therapy usage for these two therapies was 
similar between the elderly and non-elderly for each treatment 
arm, except that 60% of elderly patients in the placebo arm 
received erlotinib, whereas only 39% of non-elderly patients 
in the placebo arm received erlotinib.
Analysis of possibly treatment-related AEs in the two 
subgroups showed that 19% of elderly patients and 10% of 
non-elderly patients in the pemetrexed arm experienced at least 
one SAE. Twenty-seven percent of elderly patients and 11% of 
non-elderly patients in the pemetrexed arm and less than 1% 
of patients who received placebo in either age group experi-
enced one or more grade 3/4 common terminology criteria for 
adverse events drug-related laboratory toxicity. For grade 3/4 
common terminology criteria for adverse events drug-related 
non-laboratory toxicities, 17% of elderly patients and 11% of 
FIGURE 1.  Kaplan-Meier curves 
of progression-free survival (PFS) 
and overall survival (OS). A, B. PFS 
for elderly (A) and non-elderly (B) 
patients measured from randomiza-
tion. C, D. OS for the elderly (C) 
and non-elderly (D) measured from 
randomization. Median survival times 
in months and unadjusted hazard 
ratios are shown on each graph, 
followed by 95% confidence inter-
vals listed in parentheses. BSC, best 
supportive care; NE, not evaluable; 
CI, confidence interval; mo, months; 
HR, hazard ratio; Pem, pemetrexed; 
Plc, placebo.
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the non-elderly patients in the pemetrexed arm and 8% of the 
elderly and 4% of the non-elderly in the placebo arm expe-
rienced at least one event. In the non-elderly subgroup, two 
deaths occurred that were deemed possibly related to the study 
drug. One death caused by pneumonia occurred in the peme-
trexed arm and one death categorized as sudden death occurred 
in the placebo arm. Among the elderly patients, 1 death catego-
rized as sudden death was deemed possibly related to the study 
drug in the placebo arm; no possibly related deaths occurred 
on the pemetrexed arm in the elderly subgroup.
Analyses of possibly treatment-related AEs in the two 
subgroups showed that the occurrence of grade 1 and 2 events 
in the elderly and non-elderly were similar within each treat-
ment arm (Table 3). However, a greater percentage (15%) of 
elderly patients experienced grade 2 fatigue in the pemetrexed 
arm than non-elderly patients who received pemetrexed (9%; 
Table 3). Fatigue, anemia, and neutropenia were the most 
common Grade 3 and 4 toxicities experienced in the main-
tenance phase of the study in the pemetrexed arm (Table 3). 
A higher percentage of elderly patients experienced anemia 
and neutropenia than the non-elderly in the pemetrexed con-
tinuation maintenance arm, although importantly this did not 
translate into higher febrile neutropenia (Table 3).
Figure 2 shows the percentage of patients in which 
grade 3/4 fatigue, anemia, and neutropenia occurred over the 
course of maintenance pemetrexed treatment. Analyses of 
these AEs in patients receiving a certain number of mainte-
nance cycles, showed that the incidence of grade 3/4 fatigue 
in the pemetrexed arm was similar in the elderly and non-
elderly subgroups regardless of treatment duration (less than 
or equal to two, greater than two, greater than four, greater 
than six, greater than eight and greater than 10 cycles; Fig. 2). 
However, the incidence of neutropenia and anemia in elderly 
patients was numerically higher than in non-elderly patients 
regardless of treatment duration (Fig. 2).
During the maintenance phase, elderly and non-elderly 
patients in both treatment arms received supportive care 
(Table 4). Overall, a numerically higher percentage of elderly 
patients (17%) were hospitalized than non-elderly patients 
(10%) who received pemetrexed. A greater percentage of 
elderly patients also received transfusions (29%) than the 
non-elderly patients (17%) in the pemetrexed arm. The use of 
colony stimulating factors and erythropoietic agents was also 
numerically higher among elderly patients (Table 4).
DISCUSSION
Currently, the median age at the time of NSCLC diag-
nosis is 70 years and 30–40% of patients diagnosed are 
greater than or equal to 70 years.1,3 In current clinical practice, 
patients greater than or equal to 75 years of age are often not 
treated or are treated with a single agent only. For example, 
the Southwest Oncology Group reported that patients greater 
than or equal to 70 years constitute a large percentage of 
patients with cancer (47% in the United States); however, 
only 13% of patients enrolled in the Southwest Oncology 
Group clinical trials were greater than or equal to 70 years.19 
An additional study that reviewed publications of 100 Phase 
III trials in advanced NSCLC found that 33 of these trials 
specifically excluded older patients.20 Moreover, the aver-
age median age in all trials was 61 years and was not sig-
nificantly different between trials that specifically excluded 
elderly patients (60.9 years) and those that did not exclude 
the elderly (61.0 years).20
In line with these observations, the PARAMOUNT 
study also included a low percentage of patients aged greater 
than or equal to 70 years; only 18% of patients in the induc-
tion phase and 17% of patients in the maintenance phase were 
greater than or equal to 70 years. This bias is not limited to 
interventional randomized trials, as the percentage of elderly 
patients reported in the FRAME observational study, was 
also low (29% across the entire trial, 23% for patients who 
received pemetrexed plus platinum, and 13% for patients who 
received pemetrexed plus cisplatin).21,22 Thus, the lower per-
centage in the PARAMOUNT trial, may partially be because 
of the use of cisplatin, but not carboplatin in this trial, as 
the recent PRONOUNCE trial which evaluated carboplatin 
in combination with pemetrexed, included 32% of patients 
aged 70 years or older.23
TABLE 3.  Possibly Drug-related CTC Grade 1–4 Adverse Events, All Maintenance Cycles
Event
Elderly (≥70 Yrs) Subgroup, % Non-Elderly (<70 Yrs) Subgroup, %
Grade 1 Grade 2 Grade 3/4 Grade 1 Grade 2 Grade 3/4
Pem Plc Pem Plc Pem Plc Pem Plc Pem Plc Pem Plc
Fatigue 8 5 15 5 6 5 9 6 9 5 5 0
Anemia 8 5 10 8 12 0 4 0 10 2 6 0.7
Neutropenia 6 0 8 0 17 0 1 0 3 0.7 4 0
Febrile Neutropenia 0 0 0 0 0 0 0 0 0 0 2 0
Leukopenia 2 0 4 0 4 0 1 0 1 0 2 0
Thrombocytopenia 6 0 0 0 2 0 1 0 0.7 0 2 0
Renala 4 5 6 0 0 0 3 0.7 4 0.7 1 0
Rash 0 3 0 0 0 0 3 2 0.7 0 0 0
Edema 6 3 4 0 0 0 4 4 4 0 0 0
CTC, common terminology criteria; Pem, pemetrexed; Plc, placebo; Yrs, years.
aCreatinine, glomerular filtration rate, renal failure, and genitourinary other.
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Importantly, however, in the PARAMOUNT trial, both 
the elderly and the non-elderly were able to receive similar 
(94% versus 95%, respectively) dose intensities of cisplatin 
during induction. In addition, both elderly and non-elderly 
patients benefitted from continuation maintenance peme-
trexed, in measures of PFS and OS. Recently published results 
from the PARAMOUNT study also showed a consistent benefit 
across several additional subgroups analyzed.16,17 It is impor-
tant to note that the patients enrolled in PARAMOUNT were 
cisplatin eligible, thus they were a select population of patients 
with a good PS of 0 or 1, minimal comorbidities and a good 
prognosis. Therefore, the results in elderly patients from the 
PARAMOUNT study represent a subset of all elderly patients 
who present in the clinic. This is in line with other studies that 
have found comparable outcomes between subsets of elderly 
patients with a good PS and non-elderly patients.9–12,24
For the elderly and non-elderly populations in the 
PARAMOUNT study, and based on characteristics of patients 
receiving greater than 10 cycles, PS is confirmed as a prog-
nostic factor for survival. Patients with a PS of 0 benefit most 
from maintenance treatment, especially in the elderly sub-
group. Although comorbidities increase in frequency with 
age and could limit the treatment choices for elderly patients, 
PS score is a powerful prognostic indicator in our study, as is 
the case in non-elderly patients. Thus, the results suggest that 
elderly patients with a good PS, especially those with a PS of 
0, should not be precluded from consideration for pemetrexed 
maintenance based solely on age. Many of the elderly patients 
(90%) assigned to placebo discontinued treatment because 
of PD. More patients in the elderly compared with the non-
elderly subgroup discontinued pemetrexed treatment because 
of drug-related AEs. Renal and hematologic toxicities and 
fatigue were the main events causing discontinuation in both 
age groups. However, in the elderly, hematologic toxicities 
were the most common reason for discontinuation, whereas in 
non-elderly patients, renal events most often caused discontin-
uations. Fewer elderly patients discontinued pemetrexed treat-
ment because of PD compared with the non-elderly, indicating 
that elderly patients who can tolerate treatment perform well.
Although there was a higher PFS benefit in the elderly 
subgroup who received pemetrexed compared with the non-
elderly subgroup, this did not translate into a higher OS 
benefit for the elderly subgroup receiving pemetrexed com-
pared with the non-elderly subgroup. This may be because of 
similar percentages of elderly and non-elderly patients in the 
pemetrexed arm receiving PDT and of similar types (most 
often erlotinib and docetaxel, the approved second-line treat-
ments). However, elderly patients in the placebo arm per-
formed better than non-elderly patients in the placebo arm, 
with a 1.3 month longer median OS. This can be explained 
at least in part by the higher percentage of elderly patients in 
the placebo arm receiving PDT (83%), which was most often 
erlotinib, compared with non-elderly patients in the placebo 
arm (69%).
For all cycles considered, continuation maintenance 
pemetrexed had similar toxicity profiles in the greater than or 
equal to 70 and less than 70 years subgroups, except that the 
incidence of grade 3/4 anemia and neutropenia were numeri-
cally higher for patients greater than or equal to 70 years. The 
higher incidence of hematological toxicities may account for 
the higher resource use in elderly versus non-elderly patients, 
as adequate toxicity management is especially important in 
the elderly. Importantly, febrile neutropenia was not reported 
among elderly patients and only 2% of non-elderly patients 
experienced this AE. Hospitalizations, transfusions, colony 
stimulating factors, and the use of erythropoietic agents were 
numerically higher among elderly patients than non-elderly 
patients.
The elderly subgroup analysis described here from the 
PARAMOUNT study also confirms data from a large Phase 
III study of maintenance pemetrexed, which compared peme-
trexed versus placebo as maintenance therapy for patients who 
had not progressed after four cycles of initial non-pemetrexed 
platinum doublet.15 Retrospective age group analysis of this 
study for patients less than 70 years and those greater than 
or equal to 70 years of age, showed that maintenance peme-
trexed offered a survival benefit to all age subgroups com-
pared with placebo (adjusted HRs: 0.63 [less than 70 years] 
and 0.81 [greater than or equal to 70 years]).10 The percent-
ages of patients in each arm who experienced toxicities were 
similar among age groups.10
Historically, there have been few maintenance and treat-
ment until progressive disease trials in elderly patients with 
FIGURE 2.  Cumulative grade 3/4 fatigue, anemia, and 
 neutropenia during maintenance pemetrexed.
TABLE 4.  Summary of Supportive Care Received during the 
Maintenance Phase
Elderly (≥70 Yrs)  
Subgroup, %
Non-Elderly  
(<70 Yrs) Subgroup, %
Pem  
(N = 52)
Plc  
(N = 40)
Pem  
(N = 307)
Plc  
(N = 140)
Hospitalizations because  
of drug-related AEs
17 0 10 4
Transfusions 29 10 17 5
Concomitant medications
  Anti-infectives 33 13 34 24
  Antiemetics 25 28 41 44
  Analgesics 58 58 57 60
Erythropoietic agents 17 15 11 5
Colony stimulating factors 17 3 5 0
AE, adverse event; Pem, pemetrexed; Plc, placebo; Yrs, years.
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NSCLC patients, which is likely attributable to the toxicities 
of the drugs used. However, European Society for Medical 
Oncology guidelines currently state that fit elderly patients 
(defined as having a good PS and no/minimal comorbidities) 
should be treated the same as non-elderly patients.8 The sub-
group analyses presented here are consistent with this recom-
mendation and show that both elderly and non-elderly patients 
meeting selection criteria for maintenance with good PS who 
are cisplatin eligible can be treated by and benefit from peme-
trexed continuation therapy to a similar extent.
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